Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Calmidazolium chloride

Calmidazolium chloride (Synonyms: R 24571)

Catalog No.GC14326

Calmodulin antagonist

Products are for research use only. Not for human use. We do not sell to patients.

Calmidazolium chloride Chemical Structure

Cas No.: 57265-65-3

Size Price Stock Qty
10mg
$90.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Calmidazolium (chloride) is an inhibitor of calmodulin (CaM), inhibiting CaM-dependent phosphodiesterase and CaM-induced activation of erythrocyte calcium-transporting ATPase (IC50 = 0.15 and 0.35 µM, respectively).[1] Calmidazolium also inhibits an array of calcium-transporting ATPases, including those from heart and skeletal muscle (IC50 = 2.1 and 2.9 µM, respectively).[1] It also induces the influx of extracellular calcium through store-operated calcium channels (EC50 = 3 µM).[2],[3]

Reference:
[1]. Gietzen, K. Comparison of the calmodulin antagonists compound 48/80 and calmidazolium. Biochemistry Journal 216(3), 611-616 (1983).
[2]. Harper, J.L., and Daly, J.W. Effect of calmidazolium analogs on calcium influx in HL-60 cells. Biochemical Pharmacology 60(3), 317-324 (2000).
[3]. Peppiatt, C.M., Holmes, A.M., Seo, J.T., et al. Calmidazolium and arachidonate activate a calcium entry pathway that is distinct from store-operated calcium influx in HeLa cells. Biochemistry Journal 381(3), 929-939 (2004).

Reviews

Review for Calmidazolium chloride

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Calmidazolium chloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.